A Response to: Letter to the Editor Regarding "Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults"

Infect Dis Ther. 2024 Sep 18. doi: 10.1007/s40121-024-01039-5. Online ahead of print.

Authors

Mihaela Georgieva¹, Tianyu Sun², Ekkehard Beck¹

Affiliations

¹ Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA.
² Moderna, Inc., 325 Binney Street, Cambridge, MA, 02142, USA. tianyu.sun@modernatx.com.

PMID: 39289328
DOI: 10.1007/s40121-024-01039-5

No abstract available

Publication types

Letter